{"gene":"BCL2","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":1992,"finding":"BCL-2 protein localizes to the outer mitochondrial membrane (not inner membrane as previously suggested), as well as to the perinuclear membrane and throughout the cytoplasm, as determined by immunoelectron microscopy using three independent sample preparation methods.","method":"Immunoelectron microscopy (progressive lowering of temperature, cryosectioning, freeze-substitution) and confocal microscopy","journal":"The journal of histochemistry and cytochemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — three independent sample preparation methods all yielded the same localization result, with direct ultrastructural imaging","pmids":["1453000"],"is_preprint":false},{"year":1993,"finding":"BCL-2-mediated protection from apoptosis does not require mitochondrial respiration, as BCL-2 overexpression protects cells lacking mitochondrial DNA (and thus lacking a functional respiratory chain) from apoptosis. BCL-2 protein in overexpressing cells is associated with the nuclear envelope and endoplasmic reticulum as well as with mitochondria.","method":"Apoptosis assays in mtDNA-deficient cell lines with BCL-2 overexpression; subcellular fractionation and localization","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function model (mtDNA-deficient cells) combined with gain-of-function (BCL-2 overexpression) with clear functional readout","pmids":["8381212"],"is_preprint":false},{"year":1997,"finding":"Phosphorylation of BCL-2 at serine 70 (S70) is required for its full anti-apoptotic function. An S70A mutation abolishes phosphorylation and impairs cell survival upon IL-3 deprivation or etoposide treatment, whereas a phosphomimetic S70E mutant more potently suppresses apoptosis. Importantly, the S70A loss-of-function mutant retains the ability to heterodimerize with BAX, demonstrating that BCL-2:BAX heterodimerization alone is not sufficient for BCL-2 death-suppressor activity.","method":"Site-directed mutagenesis (serine-to-alanine and serine-to-glutamate mutations), cell survival assays, IL-3 deprivation, etoposide treatment, co-immunoprecipitation for heterodimerization","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis of active site with multiple functional readouts and mechanistic dissection of dimerization vs. phosphorylation requirements","pmids":["9115213"],"is_preprint":false},{"year":1997,"finding":"BCL-2 and BAX each independently regulate apoptosis in vivo. Genetic epistasis using Bcl-2 knockout, Bax knockout, and double-knockout mice showed that BCL-2 overexpression represses apoptosis even in the absence of BAX, while a single copy of BAX promotes apoptosis without BCL-2.","method":"Genetic epistasis using gain- and loss-of-function mouse models (Bcl-2-deficient, Bax-deficient, and double-deficient mice); thymic apoptosis and lymphocyte development phenotype analysis","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — rigorous genetic epistasis in vivo with multiple mouse genotypes and clear functional readouts, replicated across multiple tissues","pmids":["9241272"],"is_preprint":false},{"year":1998,"finding":"BCL-2 family proteins (BCL-2, BCL-XL, BAX) form ion-conductive pores in artificial membranes, suggesting a channel-forming mechanism. The pore-forming fifth and sixth alpha-helices (α5-α6) of BCL-2 are necessary but not sufficient for its cytoprotective function; deletion or swapping of α5-α6 abolishes BCL-2-mediated cell survival in human cells and yeast.","method":"In vitro channel activity assays in artificial membranes; deletion mutagenesis of α5-α6 helices; apoptosis rescue assays in human cells and yeast Saccharomyces cerevisiae","journal":"The Journal of biological chemistry / Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of channel activity combined with structure-function mutagenesis in multiple cell systems","pmids":["9812996","10200486"],"is_preprint":false},{"year":1998,"finding":"BCL-2 resides in the outer mitochondrial membrane oriented toward the cytosol and prevents mitochondrial permeability transition pore opening and release of apoptogenic proteins (e.g., cytochrome c) from mitochondria.","method":"Subcellular fractionation; mitochondrial permeability transition assays; cytochrome c release assays","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single review synthesizing functional assay data, but mechanistic claim supported by referenced experimental work","pmids":["9714773"],"is_preprint":false},{"year":2001,"finding":"The solution structure of BCL-2 (determined as a BCL-2/BCL-xL chimera) consists of 6 alpha-helices with a hydrophobic groove on the surface similar to BCL-xL. Structural comparison revealed subtle differences in the hydrophobic binding groove between BCL-2 isoforms that correlate with differences in binding affinity for BH3-domain peptides from BAD and BAK, and thus differences in anti-apoptotic activity.","method":"NMR spectroscopy; peptide binding assays with BH3 domain peptides from BAD and BAK","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure determination combined with functional peptide-binding validation in a single rigorous study","pmids":["11248023"],"is_preprint":false},{"year":1994,"finding":"BCL-2 blocks p53-mediated apoptosis and diverts p53 activity from apoptosis induction to growth arrest. BCL-2 does not affect p53 nuclear localization or protein levels in this context.","method":"Temperature-sensitive p53 mutant system; transformation assays; cell cycle analysis; immunofluorescence for p53 localization; Western blot for p53 levels","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — inducible p53 system with multiple readouts (cell death, growth arrest, p53 localization), single lab","pmids":["8139558"],"is_preprint":false},{"year":1997,"finding":"BCL-2 suppresses p53-induced apoptosis following genotoxic damage by inhibiting nuclear import of induced wild-type p53 protein, as shown by confocal microscopy and immunoblotting of nuclear/cytoplasmic fractions.","method":"Confocal microscopy; subcellular fractionation/immunoblotting; genotoxic stress (DNA damage) assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct imaging of p53 trafficking, single lab with two orthogonal methods","pmids":["9419967"],"is_preprint":false},{"year":1996,"finding":"BCL-2 acts downstream of ceramide in the cell death pathway. Overexpression of BCL-2 prevents ceramide-induced apoptosis but does not interfere with ceramide formation or ceramide-induced cell cycle arrest (retinoblastoma protein activation), placing BCL-2 function downstream of ceramide signaling but upstream of the apoptosis execution step.","method":"BCL-2 overexpression; ceramide measurement; cell death assays; cell cycle analysis; lipid second messenger pathway dissection","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis established by pathway dissection with biochemical readouts (ceramide levels, Rb activation, apoptosis), single lab","pmids":["8643573"],"is_preprint":false},{"year":1998,"finding":"BCL-2 can prevent caspase-independent cell death (NO-induced death with chromatin condensation, nuclear compaction, and mitochondrial swelling, without caspase activation), establishing that BCL-2's protective mechanism extends beyond inhibition of caspase activation.","method":"NO-induced cell death assays; peptide caspase inhibitors; p35 expression; Bax expression; BCL-2 overexpression in PC12 and HeLa cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic and pharmacological caspase-inhibition approaches combined with gain-of-function BCL-2, single lab","pmids":["9852091"],"is_preprint":false},{"year":2002,"finding":"BCL-2 overexpression increases mitochondrial volume and structural complexity without changing mitochondrial membrane potential, delta pH, or intramitochondrial K+ concentration, contrary to prior interpretations based on fluorometric dye uptake.","method":"Calibrated mitochondrial respiration measurements; membrane potential measurements (calibrated); flow cytometry particle sizing and light scattering; digitonin-permeabilized cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — rigorous calibrated biophysical measurements correcting a prior interpretation, single lab","pmids":["12207028"],"is_preprint":false},{"year":2002,"finding":"BCL-2 directly reduces the filling state of the endoplasmic reticulum Ca2+ store, and this reduction in ER Ca2+ content renders cells less sensitive to apoptotic stimuli, identifying a Ca2+ signaling mechanism for BCL-2's anti-apoptotic function.","method":"ER Ca2+ store measurements; apoptosis assays; BCL-2 overexpression in cell lines","journal":"Cell calcium","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct measurement of ER Ca2+ with functional apoptosis correlation, single lab with two orthogonal readouts","pmids":["12543100"],"is_preprint":false},{"year":2011,"finding":"BCL-2 at the mitochondria (mito-BCL-2) binds AMBRA1 under basal conditions. Upon autophagy induction, AMBRA1 is released from mito-BCL-2 and is recruited to BECLIN 1, promoting BECLIN 1-dependent autophagy. AMBRA1 can compete with both mitochondrial and ER-resident BCL-2 to bind BECLIN 1.","method":"Co-immunoprecipitation; subcellular fractionation; autophagy induction assays; overexpression and knockdown of AMBRA1, BCL-2, BECLIN 1","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP and functional autophagy assays with compartment-specific BCL-2 constructs, single lab","pmids":["21358617"],"is_preprint":false},{"year":2014,"finding":"BCL-2 directly binds and inhibits ryanodine receptors (RyRs) via its BH4 domain. BCL-2 co-immunoprecipitates with RyRs in ectopic expression systems and in native rat hippocampi; purified RyR domains interact with BCL-2's BH4 domain in pulldown and surface plasmon resonance experiments. Expression of full-length BCL-2 or electroporation of the BH4 domain peptide dampens RyR-mediated Ca2+ release in HEK293 cells and hippocampal neurons.","method":"Co-immunoprecipitation (ectopic and endogenous); pulldown with purified RyR domains; surface plasmon resonance (SPR); Ca2+ imaging in HEK293 cells and hippocampal neurons; BH4-domain peptide electroporation","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal binding methods (co-IP, pulldown, SPR) combined with functional Ca2+ release measurements in two cell types, single lab","pmids":["24762814"],"is_preprint":false},{"year":2017,"finding":"BCL-2 is ubiquitylated and degraded through a ternary complex involving ARTS (Sept4_i2) and XIAP. ARTS binds BCL-2 via its BH3 domain, bringing XIAP into proximity to act as an E3 ubiquitin ligase for BCL-2. Lysine 17 of BCL-2 is the main ubiquitylation acceptor site; a K17A BCL-2 mutant shows increased stability and enhanced anti-apoptotic potency. BCL-2 ubiquitylation is reduced in both XIAP- and Sept4/ARTS-deficient MEFs.","method":"Co-immunoprecipitation (ternary complex); site-directed mutagenesis (BH3 domain of BCL-2, K17A mutant); ubiquitylation assays; mass spectrometry; XIAP/ARTS knockout MEFs; apoptosis assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis of ubiquitylation site combined with co-IP, knockout cell lines, and mass spectrometry identification, single lab with multiple orthogonal methods","pmids":["29020630"],"is_preprint":false},{"year":2003,"finding":"NF-κB2/p100 and its processed product p52, in association with Bcl-3, transcriptionally activate the BCL-2 promoter via a κB site at position -180 that is bound only by p50 or p52 homodimers. Stable overexpression of p100/p52 induces endogenous BCL-2 expression in breast cancer cells.","method":"BCL-2 promoter-reporter transfection assays; electrophoretic mobility shift assay (EMSA); stable overexpression of p100/p52 in MCF7AZ cells; Western blot for endogenous BCL-2","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter analysis combined with endogenous protein induction by stable overexpression, single lab with two orthogonal methods","pmids":["12835724"],"is_preprint":false},{"year":2001,"finding":"c-Myc and E2F-1 suppress BCL-2 protein and mRNA levels in an ARF/p53-independent manner, and this suppression of BCL-2 mediates accelerated apoptosis upon IL-3 deprivation. Restoration of BCL-2 protein levels effectively blocks this accelerated apoptosis. DNA-binding activity of c-Myc and E2F-1 is required for BCL-2 suppression.","method":"Overexpression and DNA-binding mutant analysis of c-Myc and E2F-1; BCL-2 restoration by retroviral transduction; RT-PCR and Western blot; IL-3 deprivation apoptosis assay; dominant-negative p53","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function and DNA-binding mutant epistasis with rescue experiment, single lab","pmids":["11704823"],"is_preprint":false},{"year":1997,"finding":"BCL-2 overexpression increases telomerase activity in human cancer cells, and IL-2 deprivation-induced down-regulation of BCL-2 causes concurrent inhibition of telomerase activity, establishing a functional link between BCL-2 and telomerase regulation.","method":"Stable BCL-2 overexpression; TRAP assay for telomerase activity; IL-2 deprivation in CTLL-2 cells; cell cycle analysis","journal":"The Journal of biological chemistry","confidence":"Low","confidence_rationale":"Tier 3 / Weak — correlative assays linking BCL-2 levels to telomerase activity without direct mechanistic dissection, single lab","pmids":["9162048"],"is_preprint":false},{"year":1998,"finding":"BCL-2 can function as an adapter or docking protein in addition to its ion channel activity, and these dual activities together begin to explain how BCL-2 controls the programmed cell death pathway.","method":"Protein interaction/docking assays; channel activity assays in membranes (as reviewed)","journal":"Histology and histopathology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — review paper synthesizing available experimental data without primary new experiment reported in abstract","pmids":["9589906"],"is_preprint":false},{"year":1998,"finding":"BCL-2 promotes migration and invasion of glioma cells by activating matrix metalloproteinase-2 (MMP-2) and altering the expression of MMP-2/-3/-12, MMP-9/-12, cell surface urokinase-type plasminogen activator (u-PA), and reducing TIMP-2 expression.","method":"Ectopic BCL-2 expression in glioma sublines; spheroid migration assay; Matrigel invasion assay; fetal rat-brain aggregate invasion; zymography for MMP-2 activation; RT-PCR for MMP/TIMP/u-PA mRNA","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function with multiple functional assays and molecular mechanism (MMP activation) identified, single lab","pmids":["9872414"],"is_preprint":false},{"year":2002,"finding":"BCL-2 overexpression promotes myocyte proliferation in vivo, associated with decreased expression of cell-cycle inhibitors p21(WAF1) and p16(INK4a) and increased Mdm2-p53 complexes, identifying a non-apoptotic role for BCL-2 in cell cycle regulation.","method":"Transgenic mice overexpressing BCL-2 under α-myosin heavy chain promoter; BrdU labeling; mitotic index; immunohistochemistry for p21, p16, Mdm2-p53; co-immunoprecipitation of Mdm2-p53","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo transgenic model with multiple molecular mechanism readouts, single lab","pmids":["11983915"],"is_preprint":false}],"current_model":"BCL-2 is an integral outer mitochondrial membrane protein (also present at ER and nuclear envelope) that suppresses apoptosis by preventing mitochondrial outer membrane permeabilization and cytochrome c release through its conserved hydrophobic BH-domain groove, forming ion-conductive channels via its α5-α6 helices, binding and sequestering pro-apoptotic BH3-domain proteins, inhibiting RyR- and IP3R-mediated Ca2+ release via its BH4 domain, and undergoing regulatory phosphorylation at S70 (required for full anti-apoptotic activity) and XIAP/ARTS-mediated ubiquitylation at K17 (promoting its degradation); it additionally controls autophagy by binding BECLIN 1 and AMBRA1, and has non-canonical roles in cell migration (via MMP regulation) and proliferation (via cell-cycle inhibitor suppression)."},"narrative":{"mechanistic_narrative":"BCL-2 is the prototypical anti-apoptotic regulator of programmed cell death, an integral outer mitochondrial membrane protein oriented toward the cytosol that also resides at the nuclear envelope and endoplasmic reticulum [PMID:1453000, PMID:8381212, PMID:9714773]. It suppresses apoptosis by preventing mitochondrial permeability transition and the release of apoptogenic factors such as cytochrome c, and it acts downstream of upstream death signals including ceramide while remaining capable of blocking even caspase-independent death [PMID:9714773, PMID:8643573, PMID:9852091]. Structurally, BCL-2 folds into six alpha-helices presenting a surface hydrophobic groove whose subtle features tune its affinity for BH3-domain peptides of pro-apoptotic proteins such as BAD and BAK, while its α5–α6 helices form ion-conductive membrane channels that are necessary but not sufficient for cytoprotection [PMID:9812996, PMID:10200486, PMID:11248023]. Genetic epistasis established that BCL-2 and BAX each regulate apoptosis independently, so that BCL-2 represses death even without BAX and BCL-2:BAX heterodimerization alone does not account for its activity [PMID:9115213, PMID:9241272]. BCL-2 activity is set post-translationally: phosphorylation at serine 70 is required for full anti-apoptotic function, while ARTS-bridged, XIAP-mediated ubiquitylation at lysine 17 targets BCL-2 for degradation [PMID:9115213, PMID:29020630]. Beyond mitochondrial gatekeeping, BCL-2 controls intracellular Ca2+ by lowering ER store filling and by binding and inhibiting ryanodine receptors through its BH4 domain [PMID:12543100, PMID:24762814], regulates autophagy by sequestering AMBRA1 and competing for BECLIN 1 [PMID:21358617], and is transcriptionally controlled by opposing inputs from NF-κB2/p52–Bcl-3 (activating) and c-Myc/E2F-1 (repressing) [PMID:12835724, PMID:11704823]. Non-canonical roles include promotion of cell migration/invasion via MMP-2 activation and cell-cycle modulation through suppression of p21 and p16 [PMID:9872414, PMID:11983915].","teleology":[{"year":1992,"claim":"Resolved where BCL-2 acts in the cell, placing it at the outer mitochondrial membrane rather than the inner membrane, which reframed its mechanism around the mitochondrial surface.","evidence":"Immunoelectron microscopy by three independent preparation methods plus confocal microscopy","pmids":["1453000"],"confidence":"High","gaps":["Does not establish how BCL-2 is targeted/anchored to the membrane","Functional consequence of perinuclear/cytoplasmic pools left open"]},{"year":1993,"claim":"Showed BCL-2 protection is independent of a functional respiratory chain, decoupling its anti-apoptotic function from mitochondrial bioenergetics and pointing to a structural/signaling role across multiple membranes.","evidence":"Apoptosis assays in mtDNA-deficient cells with BCL-2 overexpression; fractionation","pmids":["8381212"],"confidence":"High","gaps":["Mechanism at ER/nuclear envelope not defined","Does not identify the protective biochemical step"]},{"year":1994,"claim":"Connected BCL-2 to the p53 tumor-suppressor axis, showing it diverts p53 output from apoptosis toward growth arrest without altering p53 levels or nuclear localization.","evidence":"Temperature-sensitive p53 system with transformation, cell-cycle, and localization readouts","pmids":["8139558"],"confidence":"Medium","gaps":["Direct molecular link to p53 machinery not defined","Single inducible system"]},{"year":1997,"claim":"Established that phosphorylation at S70 is a required regulatory switch for full anti-apoptotic activity and that BAX heterodimerization alone is insufficient, separating dimerization from death-suppression.","evidence":"S70A/S70E mutagenesis with survival assays and co-IP for BAX binding","pmids":["9115213"],"confidence":"High","gaps":["Kinase responsible for S70 phosphorylation not identified here","Structural effect of phosphorylation unknown"]},{"year":1997,"claim":"Genetic epistasis in mice proved BCL-2 and BAX act independently in vivo, refining the model away from simple obligate heterodimer titration.","evidence":"Bcl-2, Bax single- and double-knockout mice with thymic/lymphocyte phenotypes","pmids":["9241272"],"confidence":"High","gaps":["Does not define the BAX-independent effector mechanism","Tissue-specific differences not fully resolved"]},{"year":1996,"claim":"Placed BCL-2 downstream of ceramide signaling but upstream of execution, defining its position in the death pathway by epistasis.","evidence":"BCL-2 overexpression with ceramide measurement, Rb activation, and apoptosis readouts","pmids":["8643573"],"confidence":"Medium","gaps":["No direct ceramide-effector identified","Single lab"]},{"year":1997,"claim":"Extended the p53 connection by showing BCL-2 blocks genotoxin-induced apoptosis through inhibiting nuclear import of induced p53.","evidence":"Confocal imaging and nuclear/cytoplasmic fractionation under DNA damage","pmids":["9419967"],"confidence":"Medium","gaps":["Mechanism of trafficking inhibition unknown","Reconciliation with prior p53-level data incomplete"]},{"year":1998,"claim":"Defined a biophysical effector activity: BCL-2 forms ion-conductive channels via α5–α6, helices that are necessary but not sufficient for survival, linking structure to function.","evidence":"Artificial-membrane channel assays plus α5–α6 deletion/swap rescue in human cells and yeast","pmids":["9812996","10200486"],"confidence":"High","gaps":["Physiological channel substrate/conductance in vivo unproven","What else besides channel activity is required not defined here"]},{"year":1998,"claim":"Established BCL-2 prevents mitochondrial permeability transition and cytochrome c release, the central mitochondrial mechanism of its protection.","evidence":"Fractionation, permeability transition assays, and cytochrome c release assays (review synthesis)","pmids":["9714773"],"confidence":"Medium","gaps":["Review-level synthesis rather than single primary dataset","Direct molecular gating mechanism not resolved"]},{"year":1998,"claim":"Showed protection extends to caspase-independent death, broadening BCL-2's mechanism beyond blocking caspase activation.","evidence":"NO-induced death with caspase inhibitors/p35 in PC12 and HeLa cells","pmids":["9852091"],"confidence":"Medium","gaps":["Effector of caspase-independent protection unidentified","Single lab"]},{"year":2001,"claim":"Provided the structural basis for selective anti-apoptotic activity, showing a six-helix fold with a hydrophobic groove whose features dictate BH3-peptide binding affinity.","evidence":"NMR of a BCL-2/BCL-xL chimera with BAD/BAK BH3 peptide binding","pmids":["11248023"],"confidence":"High","gaps":["Chimeric construct rather than native BCL-2","Full-length membrane-embedded structure not solved"]},{"year":2002,"claim":"Identified ER Ca2+ regulation as an anti-apoptotic mechanism, showing BCL-2 lowers ER store filling to reduce apoptotic sensitivity.","evidence":"ER Ca2+ store measurements with apoptosis assays in BCL-2-overexpressing cells","pmids":["12543100"],"confidence":"Medium","gaps":["Molecular target lowering ER Ca2+ not identified here","Single lab"]},{"year":2002,"claim":"Clarified mitochondrial biophysics, showing BCL-2 alters mitochondrial volume/complexity without changing membrane potential, correcting dye-based misinterpretations.","evidence":"Calibrated respiration, potential, and particle-sizing measurements in permeabilized cells","pmids":["12207028"],"confidence":"Medium","gaps":["Functional consequence of volume change unresolved","Single lab"]},{"year":2002,"claim":"Revealed a non-apoptotic proliferative role, with BCL-2 promoting myocyte proliferation via suppression of p21/p16 and altered Mdm2-p53 complexes.","evidence":"Cardiac-specific BCL-2 transgenic mice with proliferation and cell-cycle-inhibitor readouts","pmids":["11983915"],"confidence":"Medium","gaps":["Direct link between BCL-2 and cell-cycle inhibitor regulation unknown","Tissue-specific"]},{"year":2003,"claim":"Defined transcriptional activation of BCL-2 by NF-κB2/p52–Bcl-3 through a defined κB promoter site.","evidence":"Promoter-reporter, EMSA, and stable p100/p52 overexpression with endogenous BCL-2 readout","pmids":["12835724"],"confidence":"Medium","gaps":["Cell-type generality not tested","Single lab"]},{"year":2001,"claim":"Defined transcriptional repression of BCL-2 by c-Myc and E2F-1, with BCL-2 loss mediating accelerated apoptosis, and rescue confirming causality.","evidence":"c-Myc/E2F-1 overexpression and DNA-binding mutants with BCL-2 restoration in IL-3 deprivation","pmids":["11704823"],"confidence":"Medium","gaps":["Direct vs indirect promoter action not fully resolved","Single lab"]},{"year":2011,"claim":"Linked BCL-2 to autophagy control, showing mitochondrial BCL-2 sequesters AMBRA1 and competes for BECLIN 1, releasing AMBRA1 upon autophagy induction.","evidence":"Reciprocal co-IP, fractionation, and autophagy assays with compartment-specific BCL-2 constructs","pmids":["21358617"],"confidence":"Medium","gaps":["Signal triggering AMBRA1 release not defined","Single lab"]},{"year":2014,"claim":"Established a BH4-domain Ca2+ control mechanism, with BCL-2 directly binding and inhibiting ryanodine receptors to dampen Ca2+ release.","evidence":"Co-IP (ectopic and endogenous), pulldown, SPR, and Ca2+ imaging in HEK293 and hippocampal neurons","pmids":["24762814"],"confidence":"High","gaps":["Structural basis of BH4-RyR contact not solved","In vivo physiological role in neurons not established"]},{"year":2017,"claim":"Defined the degradation pathway for BCL-2, with ARTS bridging XIAP to ubiquitylate K17 and a K17A mutant gaining stability and anti-apoptotic potency.","evidence":"Ternary-complex co-IP, K17A mutagenesis, mass spectrometry, and XIAP/ARTS-knockout MEFs","pmids":["29020630"],"confidence":"High","gaps":["Signals controlling ARTS/XIAP engagement not defined","Deubiquitylase counterpart not identified"]},{"year":null,"claim":"How BCL-2's multiple effector activities — channel formation, BH3 sequestration, ER/RyR Ca2+ control, and autophagy regulation — are integrated and prioritized within a single cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified structural model of membrane-embedded full-length BCL-2 with bound partners","Kinase for S70 not identified in this corpus","Quantitative hierarchy among mitochondrial vs ER functions unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[2,3,6,14]},{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[4]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[14,13]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[12,14]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,1,5,11]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[1,12,13]},{"term_id":"GO:0005635","term_label":"nuclear envelope","supporting_discovery_ids":[0,1]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[3,5,9,10]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[13]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[2,15]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[16,17]}],"complexes":[],"partners":["BAX","AMBRA1","BECLIN1","RYR","XIAP","ARTS","BAD","BAK"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P10415","full_name":"Apoptosis regulator Bcl-2","aliases":[],"length_aa":239,"mass_kda":26.3,"function":"Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells (PubMed:1508712, PubMed:8183370). Regulates cell death by controlling the mitochondrial membrane permeability (PubMed:11368354). Appears to function in a feedback loop system with caspases (PubMed:11368354). Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1) (PubMed:11368354). Also acts as an inhibitor of autophagy: interacts with BECN1 and AMBRA1 during non-starvation conditions and inhibits their autophagy function (PubMed:18570871, PubMed:20889974, PubMed:21358617). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release (PubMed:17418785)","subcellular_location":"Mitochondrion outer membrane; Nucleus membrane; Endoplasmic reticulum membrane; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P10415/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BCL2","classification":"Not Classified","n_dependent_lines":44,"n_total_lines":1208,"dependency_fraction":0.03642384105960265},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BCL2","total_profiled":1310},"omim":[{"mim_id":"621355","title":"KRI1 HOMOLOG; KRI1","url":"https://www.omim.org/entry/621355"},{"mim_id":"621345","title":"SPONDYLOEPIPHYSEAL DYSPLASIA, HOLLING TYPE; SEDH","url":"https://www.omim.org/entry/621345"},{"mim_id":"621230","title":"FOLLICULAR LYMPHOMA, SUSCEPTIBILITY TO, 2; FL2","url":"https://www.omim.org/entry/621230"},{"mim_id":"621095","title":"CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2JJ; CMT2JJ","url":"https://www.omim.org/entry/621095"},{"mim_id":"621094","title":"NEURONOPATHY, DISTAL HEREDITARY MOTOR, AUTOSOMAL DOMINANT 15; HMND15","url":"https://www.omim.org/entry/621094"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Mitochondria","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BCL2"},"hgnc":{"alias_symbol":["Bcl-2","PPP1R50"],"prev_symbol":[]},"alphafold":{"accession":"P10415","domains":[{"cath_id":"1.10.437.10","chopping":"10-30_89-235","consensus_level":"high","plddt":83.9552,"start":10,"end":235}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P10415","model_url":"https://alphafold.ebi.ac.uk/files/AF-P10415-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P10415-F1-predicted_aligned_error_v6.png","plddt_mean":72.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BCL2","jax_strain_url":"https://www.jax.org/strain/search?query=BCL2"},"sequence":{"accession":"P10415","fasta_url":"https://rest.uniprot.org/uniprotkb/P10415.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P10415/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P10415"}},"corpus_meta":[{"pmid":"9597135","id":"PMC_9597135","title":"BCL-2 family: regulators of cell death.","date":"1998","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9597135","citation_count":1428,"is_preprint":false},{"pmid":"20159550","id":"PMC_20159550","title":"The BCL-2 family reunion.","date":"2010","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/20159550","citation_count":1203,"is_preprint":false},{"pmid":"9916985","id":"PMC_9916985","title":"Bcl-2 family proteins.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9916985","citation_count":869,"is_preprint":false},{"pmid":"8381212","id":"PMC_8381212","title":"Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA.","date":"1993","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8381212","citation_count":730,"is_preprint":false},{"pmid":"18955968","id":"PMC_18955968","title":"Bcl-2 family proteins and cancer.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18955968","citation_count":687,"is_preprint":false},{"pmid":"25618543","id":"PMC_25618543","title":"The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update.","date":"2015","source":"Archives of toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/25618543","citation_count":554,"is_preprint":false},{"pmid":"30792387","id":"PMC_30792387","title":"BCL-2 family isoforms in apoptosis and cancer.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30792387","citation_count":544,"is_preprint":false},{"pmid":"29053143","id":"PMC_29053143","title":"MOMP, cell suicide as a BCL-2 family business.","date":"2017","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/29053143","citation_count":530,"is_preprint":false},{"pmid":"9115213","id":"PMC_9115213","title":"Bcl-2 phosphorylation required for anti-apoptosis function.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9115213","citation_count":512,"is_preprint":false},{"pmid":"23378584","id":"PMC_23378584","title":"Multiple functions of BCL-2 family proteins.","date":"2013","source":"Cold Spring Harbor perspectives in biology","url":"https://pubmed.ncbi.nlm.nih.gov/23378584","citation_count":511,"is_preprint":false},{"pmid":"9056714","id":"PMC_9056714","title":"Bcl-2 gene family in the nervous system.","date":"1997","source":"Annual review of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/9056714","citation_count":508,"is_preprint":false},{"pmid":"19043450","id":"PMC_19043450","title":"BCL-2 family antagonists for cancer therapy.","date":"2008","source":"Nature reviews. Drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/19043450","citation_count":497,"is_preprint":false},{"pmid":"37438560","id":"PMC_37438560","title":"Mechanisms of BCL-2 family proteins in mitochondrial apoptosis.","date":"2023","source":"Nature reviews. Molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/37438560","citation_count":481,"is_preprint":false},{"pmid":"28676391","id":"PMC_28676391","title":"BCL-2 proteins and apoptosis: Recent insights and unknowns.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28676391","citation_count":479,"is_preprint":false},{"pmid":"14996506","id":"PMC_14996506","title":"The role of Bcl-2 family members in tumorigenesis.","date":"2004","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/14996506","citation_count":442,"is_preprint":false},{"pmid":"29769323","id":"PMC_29769323","title":"Targeting BCL-2 regulated apoptosis in cancer.","date":"2018","source":"Open biology","url":"https://pubmed.ncbi.nlm.nih.gov/29769323","citation_count":390,"is_preprint":false},{"pmid":"8139558","id":"PMC_8139558","title":"Bcl-2 blocks p53-dependent apoptosis.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8139558","citation_count":372,"is_preprint":false},{"pmid":"14594549","id":"PMC_14594549","title":"Regulation of apoptosis by Bcl-2 family proteins.","date":"2003","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/14594549","citation_count":365,"is_preprint":false},{"pmid":"11248023","id":"PMC_11248023","title":"Solution structure of the antiapoptotic protein bcl-2.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11248023","citation_count":360,"is_preprint":false},{"pmid":"1453000","id":"PMC_1453000","title":"Ultrastructural localization of bcl-2 protein.","date":"1992","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/1453000","citation_count":357,"is_preprint":false},{"pmid":"9241272","id":"PMC_9241272","title":"Bcl-2 and Bax function independently to regulate cell death.","date":"1997","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9241272","citation_count":353,"is_preprint":false},{"pmid":"24503222","id":"PMC_24503222","title":"Many players in BCL-2 family affairs.","date":"2014","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24503222","citation_count":341,"is_preprint":false},{"pmid":"9714773","id":"PMC_9714773","title":"Bcl-2 family proteins and mitochondria.","date":"1998","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9714773","citation_count":319,"is_preprint":false},{"pmid":"31543463","id":"PMC_31543463","title":"Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.","date":"2019","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/31543463","citation_count":303,"is_preprint":false},{"pmid":"8643573","id":"PMC_8643573","title":"Bcl-2 interrupts the ceramide-mediated pathway of cell death.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8643573","citation_count":289,"is_preprint":false},{"pmid":"31776982","id":"PMC_31776982","title":"Beclin 1, Bcl-2 and Autophagy.","date":"2019","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/31776982","citation_count":257,"is_preprint":false},{"pmid":"8617450","id":"PMC_8617450","title":"bcl-2: role in epithelial differentiation and oncogenesis.","date":"1996","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8617450","citation_count":256,"is_preprint":false},{"pmid":"10200486","id":"PMC_10200486","title":"Bcl-2 family proteins as ion-channels.","date":"1998","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/10200486","citation_count":245,"is_preprint":false},{"pmid":"1510811","id":"PMC_1510811","title":"Bcl-2: a repressor of lymphocyte death.","date":"1992","source":"Immunology today","url":"https://pubmed.ncbi.nlm.nih.gov/1510811","citation_count":239,"is_preprint":false},{"pmid":"12162702","id":"PMC_12162702","title":"Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.","date":"2002","source":"Antisense & nucleic acid drug development","url":"https://pubmed.ncbi.nlm.nih.gov/12162702","citation_count":223,"is_preprint":false},{"pmid":"1908951","id":"PMC_1908951","title":"Bcl-2 maintains B cell memory.","date":"1991","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/1908951","citation_count":218,"is_preprint":false},{"pmid":"21236661","id":"PMC_21236661","title":"Apoptosis and oncogenesis: give and take in the BCL-2 family.","date":"2011","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/21236661","citation_count":215,"is_preprint":false},{"pmid":"19279228","id":"PMC_19279228","title":"Bcl-2 family on guard at the ER.","date":"2009","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19279228","citation_count":211,"is_preprint":false},{"pmid":"23173842","id":"PMC_23173842","title":"Targeting the Bcl-2 family for cancer therapy.","date":"2012","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/23173842","citation_count":209,"is_preprint":false},{"pmid":"21358617","id":"PMC_21358617","title":"Mitochondrial BCL-2 inhibits AMBRA1-induced autophagy.","date":"2011","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/21358617","citation_count":205,"is_preprint":false},{"pmid":"14657380","id":"PMC_14657380","title":"Control of Bcl-2 expression by reactive oxygen species.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14657380","citation_count":199,"is_preprint":false},{"pmid":"1868240","id":"PMC_1868240","title":"Immunolocalization of the Bcl-2 protein within hematopoietic neoplasms.","date":"1991","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/1868240","citation_count":192,"is_preprint":false},{"pmid":"22935609","id":"PMC_22935609","title":"The secrets of the Bcl-2 family.","date":"2012","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/22935609","citation_count":186,"is_preprint":false},{"pmid":"26411300","id":"PMC_26411300","title":"Discoveries and controversies in BCL-2 protein-mediated apoptosis.","date":"2015","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/26411300","citation_count":184,"is_preprint":false},{"pmid":"23783119","id":"PMC_23783119","title":"Decoding and unlocking the BCL-2 dependency of cancer cells.","date":"2013","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23783119","citation_count":184,"is_preprint":false},{"pmid":"2848196","id":"PMC_2848196","title":"Oncogenic potential of bcl-2 demonstrated by gene transfer.","date":"1988","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/2848196","citation_count":184,"is_preprint":false},{"pmid":"33799470","id":"PMC_33799470","title":"Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33799470","citation_count":173,"is_preprint":false},{"pmid":"29747654","id":"PMC_29747654","title":"BCL-2 as therapeutic target for hematological malignancies.","date":"2018","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29747654","citation_count":165,"is_preprint":false},{"pmid":"9645223","id":"PMC_9645223","title":"Mechanisms controlling cellular suicide: role of Bcl-2 and caspases.","date":"1998","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/9645223","citation_count":154,"is_preprint":false},{"pmid":"1451107","id":"PMC_1451107","title":"Bcl-2: an antidote to programmed cell death.","date":"1992","source":"Cancer surveys","url":"https://pubmed.ncbi.nlm.nih.gov/1451107","citation_count":148,"is_preprint":false},{"pmid":"11814262","id":"PMC_11814262","title":"Dysregulation of Reelin and Bcl-2 proteins in autistic cerebellum.","date":"2001","source":"Journal of autism and developmental disorders","url":"https://pubmed.ncbi.nlm.nih.gov/11814262","citation_count":145,"is_preprint":false},{"pmid":"12510149","id":"PMC_12510149","title":"BCL-2 in prostate cancer: a minireview.","date":"2003","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/12510149","citation_count":145,"is_preprint":false},{"pmid":"9162048","id":"PMC_9162048","title":"Bcl-2 modulates telomerase activity.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9162048","citation_count":143,"is_preprint":false},{"pmid":"11704823","id":"PMC_11704823","title":"Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11704823","citation_count":142,"is_preprint":false},{"pmid":"26973249","id":"PMC_26973249","title":"Bcl-2 proteins and calcium signaling: complexity beneath the surface.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26973249","citation_count":141,"is_preprint":false},{"pmid":"30037885","id":"PMC_30037885","title":"BCL-2 inhibition in AML: an unexpected bonus?","date":"2018","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/30037885","citation_count":140,"is_preprint":false},{"pmid":"9852091","id":"PMC_9852091","title":"Bcl-2 prevents caspase-independent cell death.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9852091","citation_count":140,"is_preprint":false},{"pmid":"12835724","id":"PMC_12835724","title":"NF- kappa B2/p100 induces Bcl-2 expression.","date":"2003","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/12835724","citation_count":134,"is_preprint":false},{"pmid":"11417471","id":"PMC_11417471","title":"Unwinding the loop of Bcl-2 phosphorylation.","date":"2001","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/11417471","citation_count":130,"is_preprint":false},{"pmid":"7548840","id":"PMC_7548840","title":"The bcl-2 gene family.","date":"1995","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/7548840","citation_count":128,"is_preprint":false},{"pmid":"7646485","id":"PMC_7646485","title":"bcl-2, a novel regulator of cell death.","date":"1995","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/7646485","citation_count":125,"is_preprint":false},{"pmid":"25827952","id":"PMC_25827952","title":"Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment.","date":"2015","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25827952","citation_count":122,"is_preprint":false},{"pmid":"8082073","id":"PMC_8082073","title":"bcl-2 expression in epidermal keratinocytic diseases.","date":"1994","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8082073","citation_count":117,"is_preprint":false},{"pmid":"12207028","id":"PMC_12207028","title":"Effect of Bcl-2 overexpression on mitochondrial structure and function.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12207028","citation_count":113,"is_preprint":false},{"pmid":"9529608","id":"PMC_9529608","title":"The Bcl-2 family and cell death regulation.","date":"1998","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/9529608","citation_count":111,"is_preprint":false},{"pmid":"14996501","id":"PMC_14996501","title":"Bcl-2 family members and disease.","date":"2004","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/14996501","citation_count":104,"is_preprint":false},{"pmid":"33275682","id":"PMC_33275682","title":"Therapeutic development and current uses of BCL-2 inhibition.","date":"2020","source":"Hematology. American Society of Hematology. Education Program","url":"https://pubmed.ncbi.nlm.nih.gov/33275682","citation_count":100,"is_preprint":false},{"pmid":"9872414","id":"PMC_9872414","title":"BCL-2 promotes migration and invasiveness of human glioma cells.","date":"1998","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9872414","citation_count":94,"is_preprint":false},{"pmid":"12543100","id":"PMC_12543100","title":"Endoplasmic reticulum, Bcl-2 and Ca2+ handling in apoptosis.","date":"2002","source":"Cell calcium","url":"https://pubmed.ncbi.nlm.nih.gov/12543100","citation_count":92,"is_preprint":false},{"pmid":"8888015","id":"PMC_8888015","title":"bcl-2 protein is increased in the brain from parkinsonian patients.","date":"1996","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/8888015","citation_count":92,"is_preprint":false},{"pmid":"9755641","id":"PMC_9755641","title":"The Bcl-2 gene family and apoptosis.","date":"1998","source":"Advances in biochemical engineering/biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/9755641","citation_count":91,"is_preprint":false},{"pmid":"32792521","id":"PMC_32792521","title":"Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32792521","citation_count":88,"is_preprint":false},{"pmid":"15928664","id":"PMC_15928664","title":"Bcl-2 expression predicts radiotherapy failure in laryngeal cancer.","date":"2005","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15928664","citation_count":87,"is_preprint":false},{"pmid":"8933760","id":"PMC_8933760","title":"Overexpression of Bcl-2 or Bcl-XL transgenes and photoreceptor degeneration.","date":"1996","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/8933760","citation_count":85,"is_preprint":false},{"pmid":"32307222","id":"PMC_32307222","title":"Noncanonical Cell Fate Regulation by Bcl-2 Proteins.","date":"2020","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32307222","citation_count":84,"is_preprint":false},{"pmid":"11983915","id":"PMC_11983915","title":"bcl-2 overexpression promotes myocyte proliferation.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11983915","citation_count":84,"is_preprint":false},{"pmid":"7698791","id":"PMC_7698791","title":"Analysis of the role of bcl-2 in apoptosis.","date":"1994","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/7698791","citation_count":83,"is_preprint":false},{"pmid":"9419967","id":"PMC_9419967","title":"Bcl-2 inhibits p53 nuclear import following DNA damage.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9419967","citation_count":81,"is_preprint":false},{"pmid":"7883792","id":"PMC_7883792","title":"bcl-2 in cancer, development and apoptosis.","date":"1994","source":"Journal of cell science. Supplement","url":"https://pubmed.ncbi.nlm.nih.gov/7883792","citation_count":78,"is_preprint":false},{"pmid":"22560661","id":"PMC_22560661","title":"Multipolar functions of BCL-2 proteins link energetics to apoptosis.","date":"2012","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/22560661","citation_count":75,"is_preprint":false},{"pmid":"16911824","id":"PMC_16911824","title":"Larger than life: Mitochondria and the Bcl-2 family.","date":"2006","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/16911824","citation_count":75,"is_preprint":false},{"pmid":"15246684","id":"PMC_15246684","title":"Regulation of Bcl-2 proteins during anoikis and amorphosis.","date":"2004","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/15246684","citation_count":74,"is_preprint":false},{"pmid":"29020630","id":"PMC_29020630","title":"Degradation of Bcl-2 by XIAP and ARTS Promotes Apoptosis.","date":"2017","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29020630","citation_count":74,"is_preprint":false},{"pmid":"20480043","id":"PMC_20480043","title":"Intrinsically disordered proteins in bcl-2 regulated apoptosis.","date":"2010","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/20480043","citation_count":65,"is_preprint":false},{"pmid":"28043871","id":"PMC_28043871","title":"Bcl-2 inhibitors reduce steroid-insensitive airway inflammation.","date":"2016","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28043871","citation_count":64,"is_preprint":false},{"pmid":"14996500","id":"PMC_14996500","title":"Control of proliferation by Bcl-2 family members.","date":"2004","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/14996500","citation_count":64,"is_preprint":false},{"pmid":"1286168","id":"PMC_1286168","title":"The bcl-2 oncogene and apoptosis.","date":"1992","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1286168","citation_count":63,"is_preprint":false},{"pmid":"12217750","id":"PMC_12217750","title":"Bax, Bcl-2, and p53 expression in endometrial cancer.","date":"2002","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12217750","citation_count":63,"is_preprint":false},{"pmid":"9589906","id":"PMC_9589906","title":"Mechanisms of Bcl-2 protein function.","date":"1998","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/9589906","citation_count":62,"is_preprint":false},{"pmid":"9812996","id":"PMC_9812996","title":"Cytoprotection by Bcl-2 requires the pore-forming alpha5 and alpha6 helices.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9812996","citation_count":61,"is_preprint":false},{"pmid":"28724540","id":"PMC_28724540","title":"Targeting BCL-2 in B-cell lymphomas.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28724540","citation_count":60,"is_preprint":false},{"pmid":"28212732","id":"PMC_28212732","title":"BCL-2: Long and winding path from discovery to therapeutic target.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28212732","citation_count":60,"is_preprint":false},{"pmid":"24762814","id":"PMC_24762814","title":"Bcl-2 binds to and inhibits ryanodine receptors.","date":"2014","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/24762814","citation_count":60,"is_preprint":false},{"pmid":"26956214","id":"PMC_26956214","title":"Bcl-2 is a critical mediator of intestinal transformation.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26956214","citation_count":60,"is_preprint":false},{"pmid":"9151319","id":"PMC_9151319","title":"Upregulation of Bcl-2 and elevation of ceramide in Batten disease.","date":"1997","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/9151319","citation_count":59,"is_preprint":false},{"pmid":"7868749","id":"PMC_7868749","title":"Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi.","date":"1994","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/7868749","citation_count":57,"is_preprint":false},{"pmid":"19730103","id":"PMC_19730103","title":"Targeting the Bcl-2.","date":"2009","source":"Current opinion in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19730103","citation_count":56,"is_preprint":false},{"pmid":"34913469","id":"PMC_34913469","title":"VDAC2 and the BCL-2 family of proteins.","date":"2021","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/34913469","citation_count":56,"is_preprint":false},{"pmid":"29061914","id":"PMC_29061914","title":"Therapeutics targeting Bcl-2 in hematological malignancies.","date":"2017","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/29061914","citation_count":56,"is_preprint":false},{"pmid":"8825410","id":"PMC_8825410","title":"BCL-2, a novel regulator of apoptosis.","date":"1996","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8825410","citation_count":55,"is_preprint":false},{"pmid":"19506730","id":"PMC_19506730","title":"Expression and function of bcl-2 proteins in melanoma.","date":"2008","source":"Current genomics","url":"https://pubmed.ncbi.nlm.nih.gov/19506730","citation_count":54,"is_preprint":false},{"pmid":"15367432","id":"PMC_15367432","title":"Immunogenicity of Bcl-2 in patients with cancer.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15367432","citation_count":53,"is_preprint":false},{"pmid":"27043233","id":"PMC_27043233","title":"Hematologic malignancies: newer strategies to counter the BCL-2 protein.","date":"2016","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27043233","citation_count":52,"is_preprint":false},{"pmid":"9374031","id":"PMC_9374031","title":"The bcl-2 family of proteins.","date":"1997","source":"British medical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/9374031","citation_count":52,"is_preprint":false},{"pmid":"22414090","id":"PMC_22414090","title":"Bcl-2 inhibitors: emerging drugs in cancer therapy.","date":"2012","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22414090","citation_count":50,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":38311,"output_tokens":5551,"usd":0.099099,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14069,"output_tokens":5250,"usd":0.100797,"stage2_stop_reason":"end_turn"},"total_usd":0.199896,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"BCL-2 protein localizes to the outer mitochondrial membrane (not inner membrane as previously suggested), as well as to the perinuclear membrane and throughout the cytoplasm, as determined by immunoelectron microscopy using three independent sample preparation methods.\",\n      \"method\": \"Immunoelectron microscopy (progressive lowering of temperature, cryosectioning, freeze-substitution) and confocal microscopy\",\n      \"journal\": \"The journal of histochemistry and cytochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — three independent sample preparation methods all yielded the same localization result, with direct ultrastructural imaging\",\n      \"pmids\": [\"1453000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"BCL-2-mediated protection from apoptosis does not require mitochondrial respiration, as BCL-2 overexpression protects cells lacking mitochondrial DNA (and thus lacking a functional respiratory chain) from apoptosis. BCL-2 protein in overexpressing cells is associated with the nuclear envelope and endoplasmic reticulum as well as with mitochondria.\",\n      \"method\": \"Apoptosis assays in mtDNA-deficient cell lines with BCL-2 overexpression; subcellular fractionation and localization\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function model (mtDNA-deficient cells) combined with gain-of-function (BCL-2 overexpression) with clear functional readout\",\n      \"pmids\": [\"8381212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Phosphorylation of BCL-2 at serine 70 (S70) is required for its full anti-apoptotic function. An S70A mutation abolishes phosphorylation and impairs cell survival upon IL-3 deprivation or etoposide treatment, whereas a phosphomimetic S70E mutant more potently suppresses apoptosis. Importantly, the S70A loss-of-function mutant retains the ability to heterodimerize with BAX, demonstrating that BCL-2:BAX heterodimerization alone is not sufficient for BCL-2 death-suppressor activity.\",\n      \"method\": \"Site-directed mutagenesis (serine-to-alanine and serine-to-glutamate mutations), cell survival assays, IL-3 deprivation, etoposide treatment, co-immunoprecipitation for heterodimerization\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis of active site with multiple functional readouts and mechanistic dissection of dimerization vs. phosphorylation requirements\",\n      \"pmids\": [\"9115213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"BCL-2 and BAX each independently regulate apoptosis in vivo. Genetic epistasis using Bcl-2 knockout, Bax knockout, and double-knockout mice showed that BCL-2 overexpression represses apoptosis even in the absence of BAX, while a single copy of BAX promotes apoptosis without BCL-2.\",\n      \"method\": \"Genetic epistasis using gain- and loss-of-function mouse models (Bcl-2-deficient, Bax-deficient, and double-deficient mice); thymic apoptosis and lymphocyte development phenotype analysis\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — rigorous genetic epistasis in vivo with multiple mouse genotypes and clear functional readouts, replicated across multiple tissues\",\n      \"pmids\": [\"9241272\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BCL-2 family proteins (BCL-2, BCL-XL, BAX) form ion-conductive pores in artificial membranes, suggesting a channel-forming mechanism. The pore-forming fifth and sixth alpha-helices (α5-α6) of BCL-2 are necessary but not sufficient for its cytoprotective function; deletion or swapping of α5-α6 abolishes BCL-2-mediated cell survival in human cells and yeast.\",\n      \"method\": \"In vitro channel activity assays in artificial membranes; deletion mutagenesis of α5-α6 helices; apoptosis rescue assays in human cells and yeast Saccharomyces cerevisiae\",\n      \"journal\": \"The Journal of biological chemistry / Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of channel activity combined with structure-function mutagenesis in multiple cell systems\",\n      \"pmids\": [\"9812996\", \"10200486\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BCL-2 resides in the outer mitochondrial membrane oriented toward the cytosol and prevents mitochondrial permeability transition pore opening and release of apoptogenic proteins (e.g., cytochrome c) from mitochondria.\",\n      \"method\": \"Subcellular fractionation; mitochondrial permeability transition assays; cytochrome c release assays\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single review synthesizing functional assay data, but mechanistic claim supported by referenced experimental work\",\n      \"pmids\": [\"9714773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The solution structure of BCL-2 (determined as a BCL-2/BCL-xL chimera) consists of 6 alpha-helices with a hydrophobic groove on the surface similar to BCL-xL. Structural comparison revealed subtle differences in the hydrophobic binding groove between BCL-2 isoforms that correlate with differences in binding affinity for BH3-domain peptides from BAD and BAK, and thus differences in anti-apoptotic activity.\",\n      \"method\": \"NMR spectroscopy; peptide binding assays with BH3 domain peptides from BAD and BAK\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure determination combined with functional peptide-binding validation in a single rigorous study\",\n      \"pmids\": [\"11248023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"BCL-2 blocks p53-mediated apoptosis and diverts p53 activity from apoptosis induction to growth arrest. BCL-2 does not affect p53 nuclear localization or protein levels in this context.\",\n      \"method\": \"Temperature-sensitive p53 mutant system; transformation assays; cell cycle analysis; immunofluorescence for p53 localization; Western blot for p53 levels\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — inducible p53 system with multiple readouts (cell death, growth arrest, p53 localization), single lab\",\n      \"pmids\": [\"8139558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"BCL-2 suppresses p53-induced apoptosis following genotoxic damage by inhibiting nuclear import of induced wild-type p53 protein, as shown by confocal microscopy and immunoblotting of nuclear/cytoplasmic fractions.\",\n      \"method\": \"Confocal microscopy; subcellular fractionation/immunoblotting; genotoxic stress (DNA damage) assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct imaging of p53 trafficking, single lab with two orthogonal methods\",\n      \"pmids\": [\"9419967\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"BCL-2 acts downstream of ceramide in the cell death pathway. Overexpression of BCL-2 prevents ceramide-induced apoptosis but does not interfere with ceramide formation or ceramide-induced cell cycle arrest (retinoblastoma protein activation), placing BCL-2 function downstream of ceramide signaling but upstream of the apoptosis execution step.\",\n      \"method\": \"BCL-2 overexpression; ceramide measurement; cell death assays; cell cycle analysis; lipid second messenger pathway dissection\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis established by pathway dissection with biochemical readouts (ceramide levels, Rb activation, apoptosis), single lab\",\n      \"pmids\": [\"8643573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BCL-2 can prevent caspase-independent cell death (NO-induced death with chromatin condensation, nuclear compaction, and mitochondrial swelling, without caspase activation), establishing that BCL-2's protective mechanism extends beyond inhibition of caspase activation.\",\n      \"method\": \"NO-induced cell death assays; peptide caspase inhibitors; p35 expression; Bax expression; BCL-2 overexpression in PC12 and HeLa cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic and pharmacological caspase-inhibition approaches combined with gain-of-function BCL-2, single lab\",\n      \"pmids\": [\"9852091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"BCL-2 overexpression increases mitochondrial volume and structural complexity without changing mitochondrial membrane potential, delta pH, or intramitochondrial K+ concentration, contrary to prior interpretations based on fluorometric dye uptake.\",\n      \"method\": \"Calibrated mitochondrial respiration measurements; membrane potential measurements (calibrated); flow cytometry particle sizing and light scattering; digitonin-permeabilized cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — rigorous calibrated biophysical measurements correcting a prior interpretation, single lab\",\n      \"pmids\": [\"12207028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"BCL-2 directly reduces the filling state of the endoplasmic reticulum Ca2+ store, and this reduction in ER Ca2+ content renders cells less sensitive to apoptotic stimuli, identifying a Ca2+ signaling mechanism for BCL-2's anti-apoptotic function.\",\n      \"method\": \"ER Ca2+ store measurements; apoptosis assays; BCL-2 overexpression in cell lines\",\n      \"journal\": \"Cell calcium\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct measurement of ER Ca2+ with functional apoptosis correlation, single lab with two orthogonal readouts\",\n      \"pmids\": [\"12543100\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"BCL-2 at the mitochondria (mito-BCL-2) binds AMBRA1 under basal conditions. Upon autophagy induction, AMBRA1 is released from mito-BCL-2 and is recruited to BECLIN 1, promoting BECLIN 1-dependent autophagy. AMBRA1 can compete with both mitochondrial and ER-resident BCL-2 to bind BECLIN 1.\",\n      \"method\": \"Co-immunoprecipitation; subcellular fractionation; autophagy induction assays; overexpression and knockdown of AMBRA1, BCL-2, BECLIN 1\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP and functional autophagy assays with compartment-specific BCL-2 constructs, single lab\",\n      \"pmids\": [\"21358617\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"BCL-2 directly binds and inhibits ryanodine receptors (RyRs) via its BH4 domain. BCL-2 co-immunoprecipitates with RyRs in ectopic expression systems and in native rat hippocampi; purified RyR domains interact with BCL-2's BH4 domain in pulldown and surface plasmon resonance experiments. Expression of full-length BCL-2 or electroporation of the BH4 domain peptide dampens RyR-mediated Ca2+ release in HEK293 cells and hippocampal neurons.\",\n      \"method\": \"Co-immunoprecipitation (ectopic and endogenous); pulldown with purified RyR domains; surface plasmon resonance (SPR); Ca2+ imaging in HEK293 cells and hippocampal neurons; BH4-domain peptide electroporation\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal binding methods (co-IP, pulldown, SPR) combined with functional Ca2+ release measurements in two cell types, single lab\",\n      \"pmids\": [\"24762814\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BCL-2 is ubiquitylated and degraded through a ternary complex involving ARTS (Sept4_i2) and XIAP. ARTS binds BCL-2 via its BH3 domain, bringing XIAP into proximity to act as an E3 ubiquitin ligase for BCL-2. Lysine 17 of BCL-2 is the main ubiquitylation acceptor site; a K17A BCL-2 mutant shows increased stability and enhanced anti-apoptotic potency. BCL-2 ubiquitylation is reduced in both XIAP- and Sept4/ARTS-deficient MEFs.\",\n      \"method\": \"Co-immunoprecipitation (ternary complex); site-directed mutagenesis (BH3 domain of BCL-2, K17A mutant); ubiquitylation assays; mass spectrometry; XIAP/ARTS knockout MEFs; apoptosis assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis of ubiquitylation site combined with co-IP, knockout cell lines, and mass spectrometry identification, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"29020630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"NF-κB2/p100 and its processed product p52, in association with Bcl-3, transcriptionally activate the BCL-2 promoter via a κB site at position -180 that is bound only by p50 or p52 homodimers. Stable overexpression of p100/p52 induces endogenous BCL-2 expression in breast cancer cells.\",\n      \"method\": \"BCL-2 promoter-reporter transfection assays; electrophoretic mobility shift assay (EMSA); stable overexpression of p100/p52 in MCF7AZ cells; Western blot for endogenous BCL-2\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter analysis combined with endogenous protein induction by stable overexpression, single lab with two orthogonal methods\",\n      \"pmids\": [\"12835724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"c-Myc and E2F-1 suppress BCL-2 protein and mRNA levels in an ARF/p53-independent manner, and this suppression of BCL-2 mediates accelerated apoptosis upon IL-3 deprivation. Restoration of BCL-2 protein levels effectively blocks this accelerated apoptosis. DNA-binding activity of c-Myc and E2F-1 is required for BCL-2 suppression.\",\n      \"method\": \"Overexpression and DNA-binding mutant analysis of c-Myc and E2F-1; BCL-2 restoration by retroviral transduction; RT-PCR and Western blot; IL-3 deprivation apoptosis assay; dominant-negative p53\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function and DNA-binding mutant epistasis with rescue experiment, single lab\",\n      \"pmids\": [\"11704823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"BCL-2 overexpression increases telomerase activity in human cancer cells, and IL-2 deprivation-induced down-regulation of BCL-2 causes concurrent inhibition of telomerase activity, establishing a functional link between BCL-2 and telomerase regulation.\",\n      \"method\": \"Stable BCL-2 overexpression; TRAP assay for telomerase activity; IL-2 deprivation in CTLL-2 cells; cell cycle analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — correlative assays linking BCL-2 levels to telomerase activity without direct mechanistic dissection, single lab\",\n      \"pmids\": [\"9162048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BCL-2 can function as an adapter or docking protein in addition to its ion channel activity, and these dual activities together begin to explain how BCL-2 controls the programmed cell death pathway.\",\n      \"method\": \"Protein interaction/docking assays; channel activity assays in membranes (as reviewed)\",\n      \"journal\": \"Histology and histopathology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — review paper synthesizing available experimental data without primary new experiment reported in abstract\",\n      \"pmids\": [\"9589906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BCL-2 promotes migration and invasion of glioma cells by activating matrix metalloproteinase-2 (MMP-2) and altering the expression of MMP-2/-3/-12, MMP-9/-12, cell surface urokinase-type plasminogen activator (u-PA), and reducing TIMP-2 expression.\",\n      \"method\": \"Ectopic BCL-2 expression in glioma sublines; spheroid migration assay; Matrigel invasion assay; fetal rat-brain aggregate invasion; zymography for MMP-2 activation; RT-PCR for MMP/TIMP/u-PA mRNA\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function with multiple functional assays and molecular mechanism (MMP activation) identified, single lab\",\n      \"pmids\": [\"9872414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"BCL-2 overexpression promotes myocyte proliferation in vivo, associated with decreased expression of cell-cycle inhibitors p21(WAF1) and p16(INK4a) and increased Mdm2-p53 complexes, identifying a non-apoptotic role for BCL-2 in cell cycle regulation.\",\n      \"method\": \"Transgenic mice overexpressing BCL-2 under α-myosin heavy chain promoter; BrdU labeling; mitotic index; immunohistochemistry for p21, p16, Mdm2-p53; co-immunoprecipitation of Mdm2-p53\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo transgenic model with multiple molecular mechanism readouts, single lab\",\n      \"pmids\": [\"11983915\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BCL-2 is an integral outer mitochondrial membrane protein (also present at ER and nuclear envelope) that suppresses apoptosis by preventing mitochondrial outer membrane permeabilization and cytochrome c release through its conserved hydrophobic BH-domain groove, forming ion-conductive channels via its α5-α6 helices, binding and sequestering pro-apoptotic BH3-domain proteins, inhibiting RyR- and IP3R-mediated Ca2+ release via its BH4 domain, and undergoing regulatory phosphorylation at S70 (required for full anti-apoptotic activity) and XIAP/ARTS-mediated ubiquitylation at K17 (promoting its degradation); it additionally controls autophagy by binding BECLIN 1 and AMBRA1, and has non-canonical roles in cell migration (via MMP regulation) and proliferation (via cell-cycle inhibitor suppression).\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BCL-2 is the prototypical anti-apoptotic regulator of programmed cell death, an integral outer mitochondrial membrane protein oriented toward the cytosol that also resides at the nuclear envelope and endoplasmic reticulum [#0, #1, #5]. It suppresses apoptosis by preventing mitochondrial permeability transition and the release of apoptogenic factors such as cytochrome c, and it acts downstream of upstream death signals including ceramide while remaining capable of blocking even caspase-independent death [#5, #9, #10]. Structurally, BCL-2 folds into six alpha-helices presenting a surface hydrophobic groove whose subtle features tune its affinity for BH3-domain peptides of pro-apoptotic proteins such as BAD and BAK, while its α5–α6 helices form ion-conductive membrane channels that are necessary but not sufficient for cytoprotection [#4, #6]. Genetic epistasis established that BCL-2 and BAX each regulate apoptosis independently, so that BCL-2 represses death even without BAX and BCL-2:BAX heterodimerization alone does not account for its activity [#2, #3]. BCL-2 activity is set post-translationally: phosphorylation at serine 70 is required for full anti-apoptotic function, while ARTS-bridged, XIAP-mediated ubiquitylation at lysine 17 targets BCL-2 for degradation [#2, #15]. Beyond mitochondrial gatekeeping, BCL-2 controls intracellular Ca2+ by lowering ER store filling and by binding and inhibiting ryanodine receptors through its BH4 domain [#12, #14], regulates autophagy by sequestering AMBRA1 and competing for BECLIN 1 [#13], and is transcriptionally controlled by opposing inputs from NF-κB2/p52–Bcl-3 (activating) and c-Myc/E2F-1 (repressing) [#16, #17]. Non-canonical roles include promotion of cell migration/invasion via MMP-2 activation and cell-cycle modulation through suppression of p21 and p16 [#20, #21].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Resolved where BCL-2 acts in the cell, placing it at the outer mitochondrial membrane rather than the inner membrane, which reframed its mechanism around the mitochondrial surface.\",\n      \"evidence\": \"Immunoelectron microscopy by three independent preparation methods plus confocal microscopy\",\n      \"pmids\": [\"1453000\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not establish how BCL-2 is targeted/anchored to the membrane\", \"Functional consequence of perinuclear/cytoplasmic pools left open\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Showed BCL-2 protection is independent of a functional respiratory chain, decoupling its anti-apoptotic function from mitochondrial bioenergetics and pointing to a structural/signaling role across multiple membranes.\",\n      \"evidence\": \"Apoptosis assays in mtDNA-deficient cells with BCL-2 overexpression; fractionation\",\n      \"pmids\": [\"8381212\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism at ER/nuclear envelope not defined\", \"Does not identify the protective biochemical step\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Connected BCL-2 to the p53 tumor-suppressor axis, showing it diverts p53 output from apoptosis toward growth arrest without altering p53 levels or nuclear localization.\",\n      \"evidence\": \"Temperature-sensitive p53 system with transformation, cell-cycle, and localization readouts\",\n      \"pmids\": [\"8139558\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular link to p53 machinery not defined\", \"Single inducible system\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Established that phosphorylation at S70 is a required regulatory switch for full anti-apoptotic activity and that BAX heterodimerization alone is insufficient, separating dimerization from death-suppression.\",\n      \"evidence\": \"S70A/S70E mutagenesis with survival assays and co-IP for BAX binding\",\n      \"pmids\": [\"9115213\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase responsible for S70 phosphorylation not identified here\", \"Structural effect of phosphorylation unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Genetic epistasis in mice proved BCL-2 and BAX act independently in vivo, refining the model away from simple obligate heterodimer titration.\",\n      \"evidence\": \"Bcl-2, Bax single- and double-knockout mice with thymic/lymphocyte phenotypes\",\n      \"pmids\": [\"9241272\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not define the BAX-independent effector mechanism\", \"Tissue-specific differences not fully resolved\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Placed BCL-2 downstream of ceramide signaling but upstream of execution, defining its position in the death pathway by epistasis.\",\n      \"evidence\": \"BCL-2 overexpression with ceramide measurement, Rb activation, and apoptosis readouts\",\n      \"pmids\": [\"8643573\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct ceramide-effector identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Extended the p53 connection by showing BCL-2 blocks genotoxin-induced apoptosis through inhibiting nuclear import of induced p53.\",\n      \"evidence\": \"Confocal imaging and nuclear/cytoplasmic fractionation under DNA damage\",\n      \"pmids\": [\"9419967\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of trafficking inhibition unknown\", \"Reconciliation with prior p53-level data incomplete\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Defined a biophysical effector activity: BCL-2 forms ion-conductive channels via α5–α6, helices that are necessary but not sufficient for survival, linking structure to function.\",\n      \"evidence\": \"Artificial-membrane channel assays plus α5–α6 deletion/swap rescue in human cells and yeast\",\n      \"pmids\": [\"9812996\", \"10200486\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological channel substrate/conductance in vivo unproven\", \"What else besides channel activity is required not defined here\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Established BCL-2 prevents mitochondrial permeability transition and cytochrome c release, the central mitochondrial mechanism of its protection.\",\n      \"evidence\": \"Fractionation, permeability transition assays, and cytochrome c release assays (review synthesis)\",\n      \"pmids\": [\"9714773\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Review-level synthesis rather than single primary dataset\", \"Direct molecular gating mechanism not resolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Showed protection extends to caspase-independent death, broadening BCL-2's mechanism beyond blocking caspase activation.\",\n      \"evidence\": \"NO-induced death with caspase inhibitors/p35 in PC12 and HeLa cells\",\n      \"pmids\": [\"9852091\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Effector of caspase-independent protection unidentified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Provided the structural basis for selective anti-apoptotic activity, showing a six-helix fold with a hydrophobic groove whose features dictate BH3-peptide binding affinity.\",\n      \"evidence\": \"NMR of a BCL-2/BCL-xL chimera with BAD/BAK BH3 peptide binding\",\n      \"pmids\": [\"11248023\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chimeric construct rather than native BCL-2\", \"Full-length membrane-embedded structure not solved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identified ER Ca2+ regulation as an anti-apoptotic mechanism, showing BCL-2 lowers ER store filling to reduce apoptotic sensitivity.\",\n      \"evidence\": \"ER Ca2+ store measurements with apoptosis assays in BCL-2-overexpressing cells\",\n      \"pmids\": [\"12543100\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular target lowering ER Ca2+ not identified here\", \"Single lab\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Clarified mitochondrial biophysics, showing BCL-2 alters mitochondrial volume/complexity without changing membrane potential, correcting dye-based misinterpretations.\",\n      \"evidence\": \"Calibrated respiration, potential, and particle-sizing measurements in permeabilized cells\",\n      \"pmids\": [\"12207028\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of volume change unresolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Revealed a non-apoptotic proliferative role, with BCL-2 promoting myocyte proliferation via suppression of p21/p16 and altered Mdm2-p53 complexes.\",\n      \"evidence\": \"Cardiac-specific BCL-2 transgenic mice with proliferation and cell-cycle-inhibitor readouts\",\n      \"pmids\": [\"11983915\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct link between BCL-2 and cell-cycle inhibitor regulation unknown\", \"Tissue-specific\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined transcriptional activation of BCL-2 by NF-κB2/p52–Bcl-3 through a defined κB promoter site.\",\n      \"evidence\": \"Promoter-reporter, EMSA, and stable p100/p52 overexpression with endogenous BCL-2 readout\",\n      \"pmids\": [\"12835724\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-type generality not tested\", \"Single lab\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined transcriptional repression of BCL-2 by c-Myc and E2F-1, with BCL-2 loss mediating accelerated apoptosis, and rescue confirming causality.\",\n      \"evidence\": \"c-Myc/E2F-1 overexpression and DNA-binding mutants with BCL-2 restoration in IL-3 deprivation\",\n      \"pmids\": [\"11704823\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect promoter action not fully resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Linked BCL-2 to autophagy control, showing mitochondrial BCL-2 sequesters AMBRA1 and competes for BECLIN 1, releasing AMBRA1 upon autophagy induction.\",\n      \"evidence\": \"Reciprocal co-IP, fractionation, and autophagy assays with compartment-specific BCL-2 constructs\",\n      \"pmids\": [\"21358617\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signal triggering AMBRA1 release not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established a BH4-domain Ca2+ control mechanism, with BCL-2 directly binding and inhibiting ryanodine receptors to dampen Ca2+ release.\",\n      \"evidence\": \"Co-IP (ectopic and endogenous), pulldown, SPR, and Ca2+ imaging in HEK293 and hippocampal neurons\",\n      \"pmids\": [\"24762814\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of BH4-RyR contact not solved\", \"In vivo physiological role in neurons not established\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined the degradation pathway for BCL-2, with ARTS bridging XIAP to ubiquitylate K17 and a K17A mutant gaining stability and anti-apoptotic potency.\",\n      \"evidence\": \"Ternary-complex co-IP, K17A mutagenesis, mass spectrometry, and XIAP/ARTS-knockout MEFs\",\n      \"pmids\": [\"29020630\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals controlling ARTS/XIAP engagement not defined\", \"Deubiquitylase counterpart not identified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How BCL-2's multiple effector activities — channel formation, BH3 sequestration, ER/RyR Ca2+ control, and autophagy regulation — are integrated and prioritized within a single cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified structural model of membrane-embedded full-length BCL-2 with bound partners\", \"Kinase for S70 not identified in this corpus\", \"Quantitative hierarchy among mitochondrial vs ER functions unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [2, 3, 6, 14]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [14, 13]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [12, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005741\", \"supporting_discovery_ids\": [0, 5]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 1, 5, 11]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [1, 12, 13]},\n      {\"term_id\": \"GO:0005635\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [3, 5, 9, 10]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [2, 15]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [16, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"BAX\", \"AMBRA1\", \"BECLIN1\", \"RyR\", \"XIAP\", \"ARTS\", \"BAD\", \"BAK\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}